Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 12:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,535 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Immunoglobulin Disease Clear all
Completed Phase 1Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

NCT02061761
View directory record Official record
Conditions
Hematologic Neoplasms
Interventions
BMS-986016, BMS-936558
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
8
States / cities
Baltimore, Maryland • Boston, Massachusetts • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Sep 25, 2026, 12:55 AM EDT
Completed No phase listed Observational

Prospective Natural History Study of Smoking, Immune Cell Profiles, Epigenetics and COVID-19

NCT04403386
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
30 Years to 55 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 25, 2026, 12:55 AM EDT
Completed Phase 1 Interventional

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

NCT01176474
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
NY-ESO-1 157-165 (165V), Nivolumab, gp100:280-288 (288V), Montanide ISA 51 vegetable grade (VG), Ipilimumab, Apheresis Procedure
Biological · Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
16 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Sep 25, 2026, 12:55 AM EDT
Completed Phase 1 Interventional

Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease

NCT00733642
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-04360365 1 mg/kg, PF-04360365 3 mg/kg, PF-04360365 5 mg/kg, PF-04360365 10 mg/kg
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Glendale, California • Eatontown, New Jersey • Oakhurst, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 27, 2009 · Synced Sep 25, 2026, 12:55 AM EDT
Completed Phase 3 Interventional

Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency

NCT01406470
View directory record Official record
Conditions
Immunologic Deficiency Syndrome
Interventions
Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™
Drug
Lead sponsor
Green Cross Corporation
Industry
Eligibility
2 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
9
States / cities
Birmingham, Alabama • North Palm Beach, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Sep 25, 2026, 12:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults

NCT00715910
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Nimenrix, Blood sampling
Biological · Procedure
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years to 30 Years
Enrollment
818 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
10
States / cities
Daly City, California • Fairfield, California • Redwood City, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2014 · Synced Sep 25, 2026, 12:55 AM EDT
Completed Phase 1 Interventional

Monoclonal Antibody in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT00058396
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
lumiliximab
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Sep 25, 2026, 12:55 AM EDT
Completed Phase 2 Interventional Results available

The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis

NCT02632786
View directory record Official record
Conditions
AL Amyloidosis
Interventions
NEOD001, Placebo
Drug
Lead sponsor
Prothena Biosciences Ltd.
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
19
States / cities
Duarte, California • Stanford, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Sep 25, 2026, 12:55 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563).

NCT00768079
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Benralizumab
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
9
States / cities
Tampa, Florida • Springfield, Massachusetts • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Sep 25, 2026, 12:55 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

NCT04594642
View directory record Official record
Conditions
B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
Interventions
AZD0486 IV
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
9
States / cities
Tampa, Florida • Louisville, Kentucky • New Brunswick, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 25, 2026, 12:55 AM EDT
Recruiting Phase 1Phase 2 Interventional

PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56

NCT04199741
View directory record Official record
Conditions
Small Cell Lung Cancer, Small Cell Lung Carcinoma
Interventions
89Zr-DFO-SC16.56, SC16.56, Phase I, Cohort 2, SC16.56, Phase I, Cohort 3, SC16.56, Phase II
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 25, 2026, 12:55 AM EDT
Completed Phase 1Phase 2 Interventional

Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer

NCT00043823
View directory record Official record
Conditions
Lung Cancer
Interventions
Avastin, Tarceva
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Sep 25, 2026, 12:55 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

NCT07181161
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
AZD0516, AZD9574
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Male only
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
Fayetteville, Arkansas • Los Angeles, California • Towson, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 25, 2026, 12:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

AFM13 in Relapsed/Refractory Cutaneous Lymphomas

NCT03192202
View directory record Official record
Conditions
Lymphoma, T-Cell, Cutaneous
Interventions
AFM13
Drug
Lead sponsor
Ahmed Sawas
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Sep 25, 2026, 12:55 AM EDT
Terminated Phase 1 Interventional

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma

NCT03486067
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CC-93269
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
9
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Sep 25, 2026, 12:55 AM EDT
Terminated Phase 2 Interventional Results available

Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721

NCT02682407
View directory record Official record
Conditions
IgAN, LN, MN, C3G
Interventions
OMS721 (narsoplimab)
Biological
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Denver, Colorado • Augusta, Georgia • Lawrenceville, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 25, 2026, 12:55 AM EDT
Withdrawn Phase 2 Interventional

Monoclonal Antibody Therapy and Colony- Stimulating Factor in Treating Patients With Metastatic Colorectal Cancer

NCT00002664
View directory record Official record
Conditions
Colorectal Cancer
Interventions
edrecolomab, sargramostim
Biological
Lead sponsor
James Ahlgren
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Sep 25, 2026, 12:55 AM EDT
Completed Phase 1 Interventional Results available

Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS

NCT01300572
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Secondary Acute Myeloid Leukemia
Interventions
Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate, Indium In 111 Anti-CD45 Monoclonal Antibody BC8, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Total-Body Irradiation, Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8
Procedure · Drug · Biological + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Sep 25, 2026, 12:55 AM EDT
Terminated Phase 1 Interventional Results available

A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

NCT03922477
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Atezolizumab, Hu5F9-G4
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Sacramento, California • New Haven, Connecticut • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2022 · Synced Sep 25, 2026, 12:55 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

NCT03474107
View directory record Official record
Conditions
Ureteral Cancer, Urothelial Cancer, Bladder Cancer
Interventions
Enfortumab Vedotin, Docetaxel, Vinflunine, Paclitaxel
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
25
States / cities
Orange, California • Sacramento, California • Whittier, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 25, 2026, 12:55 AM EDT
Terminated Phase 1 Interventional

A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)

NCT02641002
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions
CC-90002
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Sep 25, 2026, 12:55 AM EDT
Terminated Phase 3 Interventional Results available

Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.

NCT04913675
View directory record Official record
Conditions
Covid19
Interventions
Sotrovimab
Biological
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
12 Years and older
Enrollment
1,065 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
48
States / cities
Anniston, Alabama • Mesa, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Sep 25, 2026, 12:55 AM EDT
Completed No phase listed Observational

Immune Responses to Antigens in Non-infectious Eye Inflammatory Diseases

NCT00357071
View directory record Official record
Conditions
Eye Diseases
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
6 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 25, 2026, 12:55 AM EDT
Completed Phase 2 Interventional Results available

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

NCT00445965
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin), Metastatic Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma, Small Intestine Cancer
Interventions
DNA analysis, immunologic technique, pharmacological study, iodine I 131 monoclonal antibody 3F8, 131I-3F8
Genetic · Other · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Sep 25, 2026, 12:55 AM EDT